Translate
Subscribe to Blog via Email
Ronny Allan
Background
Some people on hear the terms “tumour markers” and “hormone levels” when they are diagnosed with Neuroendocrine Cancer. Most of them will have had a form of medical testing at some point in their life, i.e. the sampling and testing of blood, urine, saliva, stool or body tissue. In a nutshell, the medical staff are just measuring the content of a ‘substance’ and then taking a view whether this is normal or not based on pre-determined ranges. These tests are normally done as a physician’s reaction to symptom presentation or maintenance/surveillance of an existing diagnosed condition. Sometimes, abnormal results will lead to more specialist tests.
In cancer, these tests are frequently called ‘markers’. Most tumour markers are made by normal cells as well as by cancer cells; however, they are produced at much higher levels in cancerous conditions. These substances can be found in the blood, urine, stool, tumour tissue, or other tissues or bodily fluids of some patients with cancer. Most tumour markers are proteins. However, more recently, patterns of gene expression and changes to DNA have also begun to be used as tumour markers, e.g. see NETest below. Many different tumour markers have been characterised and are in clinical use. Some are associated with only one type of cancer, whereas others are associated with two or more cancer types. No “universal” tumour marker that can detect any type of cancer has been found.
There are some limitations to the use of tumour markers. Sometimes, noncancerous conditions can cause the levels of certain tumour markers to increase. In addition, not everyone with a particular type of cancer will have a higher level of a tumour marker associated with that cancer. Moreover, tumour markers have not been identified for every type of cancer. Tumour markers are not foolproof and other tests and checks are usually needed to learn more about a possible cancer or recurrence.
I’d also like to talk about a group of associated tests, in particular, hormone levels as these tests are really important to help determine the type of Neuroendocrine Tumour. NETs will sometimes over-secrete hormones, and this can give clues to the type. The constraints mentioned above apply to hormone levels and other tests to a certain extent.
Sequencing of marker testing – diagnosis
The sequencing of marker testing may have been different for many patients. In my own experience, I had a biopsy and then the biochemical checks were carried out. So regardless of the results of my marker tests, I was to be diagnosed with NETs. Those with lengthy and difficult diagnostic phases will perhaps have had a different sequence with the biochemical markers providing evidence for further tests to formally diagnose. Markers alone will normally not be enough for a diagnosis, but they do, however, feed into the treatment plan and provide a baseline at diagnosis and for tracking going forward.
What this article will not cover
Routine Testing – the post will not cover routine blood tests (i.e. complete blood count etc). Although they may point to a problem, these tests do not necessarily diagnose a particular type of NET without other supporting evidence (they can give clues though).
Biopsy Testing – Technically, the Immunohistochemical ‘stains’ used in biopsy testing are tumour markers, but I’ll not be discussing that today. I did cover the output of biopsies in my blog on Stages and Grades.
Genetic Testing. This is very specialised, but you may find my Genetics and NETs article is of interest.
Interpreting test results – International/National/Regional differences
The use of markers tends to be different on an international basis, e.g. specific marker tests can be developed in-country by independent labs. Testing can also vary in the same country as in-country labs use different commercially available ‘testing kits’. Not all tests are available in all countries.
Reference ranges can be dependent on many factors, including patient age, gender, sample population, and test method, and numeric test results can have different meanings in different laboratories. The lab report containing your test results should include the relevant reference range for your test(s). Please consult your doctor or the laboratory that performed the tests to obtain the reference range if you do not have the lab report. Moreover, the ‘normal’ test range can vary from hospital to hospital, even within the same tests. I suspect clinical staff have their own versions of risk thresholds when dealing with test results. Even when results are just above or below, individual physicians can take their own view in a subjective manner. Testing is best done at the same lab each time if possible.
There’s a great website called LabTestsOnline which can describe each test. It’s peer-reviewed, non-commercial and patient-focused but just please note you should always refer to your own lab ‘normal ranges’ which will be printed on your test results. For these reasons, you will not find reference ranges for the majority of tests described on this web site. The link above will take you to the list of ‘country’ affiliated versions with specific information on a country basis.
Here’s some tips I always give people:
1 – Always try to get your own copy of results. Unless you have an online app for this purpose, get them on paper as this should give your reference ranges which are important for asking question in patient online groups. Track them yourself (I use a spreadsheet).
2 – When comparing results inside patient forums, always add the range and if possible, the unit of measurement (i.e. g/L, mmol/L, umol/L etc etc). Failure to do this can at best confuse, and at worst frighten patients. Compare apples with apples not with pears! (this is why it’s important to know the unit of measure and the reference range in addition to the figure).
3 – Don’t get too excited about rises if the test is still inside the normal range – normal is normal!
4 – Don’t get too excited about rises taking you just outside of normal range – your doctors are looking for bigger spikes.
5. Don’t get too excited about a single test result, your doctors are looking for trends, a single test result is not much to go on.
The Anatomy
Certain tests can be anatomy related so to add context and to prevent big repetitive lists when using the terms ‘foregut’, ‘midgut’ and ‘hindgut’, you may find this graphic useful.
Markers
Although some routine blood markers (complete blood count etc) are useful in NETs, it’s pretty much impossible to cover these in any general detail. I’m going to focus on tumour and hormone associated markers
There are many markers involved with NETs. Some do different jobs, and some are just variants measuring the same thing (more or less efficiently). You may also see something called ‘gold standard’ in reference to NET Tumour markers. Although thinking is changing (more on this below) and can vary from country to country, it is generally accepted that Chromogranin A is the gold standard markers for tumour bulk. I’m also aware that US doctors are reducing the dependency on CgA and using Pancreastatin instead (although many are measuring both indicating that Pancreastatin is also not reliable).
NETs are known to be heterogeneous in nature (i.e. consisting of or composed of dissimilar elements; not having a uniform quality throughout). Whilst some markers can be used widely, it follows that there are many very specialist marker tests for individual types of NET. I think this applies to 3 broad categories of NETs: Tumours known to potentially oversecrete Serotonin and perhaps others (mainly midgut), Pancreatic NETs (or pNETs) secreting various hormones by type; and other less common types and/or syndromes which might be considered by some to be even more complex than the former two and in some cases, there are big overlaps.
Another interesting thing about NET markers is that an undiagnosed patient may undergo several specialist tests to eliminate the many possibilities that are being presented as vague and common symptoms. Sometimes this is necessary to eliminate or ‘home in’ on a tumour type or syndrome/hormone involved (it’s that jigsaw thing again!).
Markers too can be divided into broad categories, those measuring how much tumour is in your body and its growth potential and those measuring how functional (or not) those tumours are. The latter can probably be expanded to measure/assess excess hormone secretion and syndromes.
Markers for measuring Tumour bulk or load/growth prediction
Chromogranin (plasma/blood test)
Chromogranin is an acidic protein released from chromaffin cells and nerve terminals. This statement alone might explain why it is a good marker to use with NETs for measuring tumour bulk. Depending on the test kit being used, you may see test results for Chromogranin A (CgA) and Chromogranin B (CgB) – the inclusion of CgB tends to be confined to Europe. My comprehensive post on Chromogranin A can be found by clicking here or on the picture below:
Pancreastatin
In effect, this marker does the same job as CgA. Interestingly, Pancreastatin is actually a fragment of the CgA molecule. There have been many studies (mainly in the US) indicating this is a more efficient marker than CgA, and not only because it is not influenced by the use of PPI. It has also been suggested that it’s more sensitive than CgA and therefore capable of detecting early increases in tumour burden. It has also been suggested it can be an indication of tumour ‘activity’ (whatever that means). It is widely used in the US and some physicians will use it in preference to CgA (…..although from what I read, CgA also seems to be tested alongside). I’m starting to see this mentioned in the UK.
Neurokinin A (NKA)
This is not a well-publicised test. However, it is something used in USA, but I’d like to hear from others to validate its use elsewhere. In a nutshell, this test, which only applies to well-differentiated midgut NETs, appears to have some prognostic indication. I discovered this test in the ISI NET Guidance, and it’s backed up by a study authored by names such as Woltering, O’Dorisio, Vinik, et al. This is not a one-off test but one designed to be taken serially, i.e. a number of consecutive tests. These authors believe that NKA can also aid in the early identification of patients with more aggressive tumors, allowing for better clinical management of these patients. NKA is sometimes called Substance K.
Neuron-Specific Enolase (NSE)
In patients with suspected NET who have no clear elevations in the primary tumour markers used to diagnose these conditions, an elevated serum NSE level supports the clinical suspicion. Neuron-Specific Enolase (NSE) is a neuron-specific isomer of the enolase enzyme, found in neurons and neuroendocrine cells. Assessment of NSE alone is rarely adequate for diagnostic purposes of NETs, given that only 30 to 50%, in fact, secrete NSE; additionally, NSE has low specificity and sensibility for differentiating NET from non-endocrine tumors. Serum NSE concentrations are often increased in patients with other diseases, such as thyroid cancer, prostate carcinoma, neuroblastoma, and small cell lung carcinoma (SCLC); on the contrary, neuronal damage is associated with decreased levels of NSE. In the presence of a pulmonary mass, high levels of NSE are often suggestive of an SCLC and have negative prognostic value. In fact, overexpression of NSE by all tumors, including NETs, is usually suggestive of poorly differentiated tumors, and thus of poor prognosis for higher-grade cancers. Persistence of high NSE levels following treatment is usually considered a negative prognostic marker for SCLC, but there is no solid evidence in regard to post-treatment NSE levels for NETs. Assessing NSE and CgA at the same time as part of the diagnostic process could possibly increase the reliability of the measurement, providing further proof of the presence of a NET; however, given the non-specific nature of both markers, these tests provide little information concerning the localization of the primary tumor. Sansone A, Lauretta R, Vottari S, Chiefari A, Barnabei A, Romanelli F, Appetecchia M. Specific and Non-Specific Biomarkers in Neuroendocrine Gastroenteropancreatic Tumors. Cancers (Basel). 2019 Aug 4;11(8):1113. doi: 10.3390/cancers11081113. PMID: 31382663; PMCID: PMC6721814.
NETest by Wren Laboratories
This has been around for some time but hasn’t really taken off. It is more of a molecular test which is way tumour markers for cancer is heading. Read more here or see special section below. Click here.
Markers for measuring Tumour functionality/hormone/peptide levels
So far, I’ve covered basic tumour markers which have a tumour bulk and/or prognostic indication. This section is a slightly more complex area and many more tests are involved. There’s often a correlation between CgA/Pancreastatin and these type of markers in many patients i.e. a serial high level of CgA might indicate a high level of tumour bulk and therefore increased production of a hormone in patients with a syndrome or oversecreting tumour. However, it frequently does not work out like that, particularly when dealing with non-functioning tumours.
The type of marker for this element of NET diagnosis and surveillance will vary depending on the type of NET and its location (to a certain extent). Like tumour bulk/growth, there might be different options or test variants on an international basis. There are too many to list here, so I’ll only cover the most common.
Serotonin Secreting Tumours (mainly midgut)
There are a few markers in use for measuring the functionality of this grouping of tumours. This tumour group has a tendency to secrete excess amounts of the hormone Serotonin although it differs depending on the area of the primary. For example, hindgut tumours tend to secret lower levels than foregut and midgut and therefore this test may present within range. Please also note there may be other hormones of note involved. The antiquated and misleading term ‘Carcinoid’ is sometimes used as a descriptor for these tumours and more and more NET scientific organisations and specialists are now avoiding use of this term.
5HIAA. This is a metabolite of Serotonin thus why it’s a useful thing to measure to assess functionality in this grouping of tumours. 5HIAA is actually the ‘gold standard’ test for functioning serotonin secreting tumours. There is a totally separate article on 5-HIAA which you can read by clicking here or on the picture below.
Substance P. A substance associated with foregut and midgut tumours. It is a vasoactive protein that can cause wheezing, diarrhea, tachycardia, flushing
Histamines – Usually associated with foregut tumors. Appears to be involved in patchy rashes and flushing. More likely to be seen in Gastric and Lung tumours than midgut though. The advice in the ISI NET book is no antihistamine medication to be taken for 48 hours prior to blood draw.
Gastric NETs (Stomach) (Foregut)
Testing will be different depending on the Type:
- Type 1 – Typical Low Grade, tends to be caused by atrophic gastritis.
- Type 2 – Atypical Intermediate Grade and tends to be caused by gastrin secreting tumours. Type 2 normally needs a check for MEN1/Zollinger-Ellison Syndrome.
- Type 3 – Tend to be larger and more aggressive tumours.
The key makers are CgA and Gastrin although Gastrin may not be elevated in Type 3. Gastrin ph is useful to differentiate between Type 1 and Type 2. 5HIAA can be considered but Carcinoid Syndrome is almost unheard of in Gastric NETs.
Read more about Gastric NETs here:
NETs of the Pancreas (pNETs) – (Foregut)
pNETs can be very difficult to diagnose and not only because they share some presentation similarities to their exocrine counterparts. Some pNETs actually comprise tumours arising in the upper part of the duodenum (small intestine) close to the Pancreas. Moreover, more than half of pNETs are non-functional which increases the difficulty in suspecting and then finding the tumours. However, where there is clinical presentation or suspicion, these symptoms can lead to the appropriate testing to support the output of scans. The fasting gut profile mentioned above can be useful in identifying the offending hormones when the type of NET is not yet known.
Gut Hormones (Glucagon, Gastrin, VIP, Somatostatin, Pancreatic Polypeptide)
A gut hormone screen is used for the diagnosis of a variety of endocrine tumours of the pancreas area. Analysis includes gastrin, VIP, somatostatin, pancreatic polypeptide, and glucagon, but there may be others depending on processes used by your ordering specialist or hospital.
Notes:
1. You may see this referred to as a ‘Fasting Gut Profile’ or a ‘Fasting Gut Hormone Profile’.
2. The individual hormones measured seem to differ between hospital labs.
3. The fasting conditions also vary between hospitals and labs but all agree the conditions are critical to the most accurate results. Always ask for instructions if you’re offered this test.
The gastrin test is usually requested to help detect high levels of gastrin and stomach acid. It is used to help diagnose gastrin-producing tumours called gastrinomas, Zollinger-Ellison (ZE) syndrome, and hyperplasia of G-cells, specialised cells in the stomach that produce gastrin. It may be measured to screen for the presence of multiple endocrine neoplasia type I (MEN) It may be used if a person has abdominal pain, diarrhoea, and recurrent peptic ulcers. A gastrin test may also be requested to look for recurrence of disease following surgical removal of a gastrinoma.
Vasoactive intestinal peptide (VIP) measurement is required for diagnosis of pancreatic tumour or a ganglioneuroma which secretes VIP. Administration of VIP to animals causes hyperglycaemia, inhibition of gastric acid, secretion of pancreatic bicarbonate and of small intestinal juice, and a lowering of systemic blood pressure with skin flush. These features are seen in patients with a tumour of this type which is secreting VIP.
Glucagon is measured for preoperative diagnosis of a glucagon-producing tumour of the pancreas in patients with diabetes and a characteristic skin rash (necrolytic migratory erythema).
Pancreatic polypeptide (PP) production is most commonly associated with tumours producing vasoactive intestinal polypeptide and with carcinoid syndrome and, less commonly, with insulinomas and gastrinomas.
When secreted by endocrine tumours, somatostatin appears to produce symptoms similar to those seen on pharmacological administration, i.e. steatorrhoea, diabetes mellitus and gall stones.
There are several types of functional pNETs, each with its own syndrome or hormone issue and the Gut Hormone Profile mentioned above is one way to check whether a pNET is functional or non-functional, or at least provide further clues. When they are suspected due to the presenting symptoms, the markers that could be used are listed below. These types of tumours are complex and can be related to one or more syndromes. A patient may be tested using multiple markers to include or exclude these. Depending on other factors, some physicians may recommend additional marker testing in addition to the most common types below.
Insulinoma – Insulin, Proinsulin, C-peptide
Gastrinoma– Gastrin, Gastrin pH
Glucagonoma – Glucagon, Insulin, Pancreatic Polypeptide (PP), Adrenocorticotropic hormone (ACTH)
VIPoma – Vasoactive Intestinal Polypeptide (VIP), Electrolytes (due to profuse diarrhea)
Somatostatinoma – Somatostatin (plasma somatostatin like immunoreactivity)
PPoma – Pancreatic Polypeptide (PP)
Other NETs/Syndromes
Hindgut NET. NETs of the colon or rectum are rarely functional. This area is normally unable to manufacture serotonin from its precursors. However, symptomatic cases may benefit from a 5HIAA test.
Pheochromocytoma/Paraganglioma – Adrenaline-producing tumours. Plasma and urine catecholamines, plasma free total metanephrines, urine total metanephrines, vanillylmandelic acid (VMA). Read more here.
Medullary Thyroid Cancer. Medullary thyroid cancer (MTC) starts as a growth of abnormal cancer cells within the thyroid – the parafollicular C cells. In the hereditary form of medullary thyroid cancer (~20% of cases, often called Familial MTC or FMTC), the growth of these cells is due to a mutation in the RET gene which was inherited. This mutated gene may first produce a premalignant condition called C cell hyperplasia. The parafollicular C cells of the thyroid begin to have unregulated growth. In the inherited forms of medullary thyroid cancer, the growing C cells may form a bump or nodule in any portion of the thyroid gland. Unlike papillary and follicular thyroid cancers, which arise from thyroid hormone-producing cells, medullary thyroid cancer originates in the parafollicular cells (also called C cells) of the thyroid.
These cancer cells make a different hormone called calcitonin, which has nothing to do with the control of metabolism in the way thyroid hormones do. The other test often seen in MTC is Carcinoembryonic Antigen (CEA). CEA is a protein that is usually found in the blood at a very low level but might rise in certain cancers, such as medullary thyroid cancer. There is no direct relationship between serum calcitonin levels and extent of medullary thyroid cancer. However, trending serum calcitonin and CEA levels can be a useful tool for doctors to consider in determining the pace of change of a patient’s medullary cancer. There is one more test that can be used to identify patients with MCT who have normal baseline levels of calcitonin – the pentagastrin stimulation test. Pentagastrin normally stimulates the secretion of calcitonin from the C cell. Women may not respond due to the presence of estrogens. The response in persons with MCT is an exaggeration of the normal response to pentagastrin. Be aware there is a familial variant of MCT (often called FMCT) and it’s always useful to identify members of a family with a known familial form of MEN2 and MCT (RET mutation).
(please note there are extremely rare occurrences of elevated calcitonin from places outside the thyroid – read more here.)
Parathyroid– Parathyroid hormone (PTH), Serum Calcium. Parathyroid hormone (PTH) is secreted from four parathyroid glands, which are small glands in the neck, located behind the thyroid gland. Parathyroid hormone regulates calcium levels in the blood, largely by increasing the levels when they are too low. A primary problem in the parathyroid glands, producing too much parathyroid hormone causes raised calcium levels in the blood (hypercalcaemia – primary hyperparathyroidism). You may also be offered an additional test called Parathyroid Hormone-Related Peptide (PTHrP). They would probably also measure Serum Calcium in combination with these types of tests. The parathyroid is one of the ‘3 p’ locations often connected to Multiple Endocrine Neoplasia – MEN 1 – see MEN below.
Pituitary/Cushings – Adrenocorticotropic hormone (ACTH), Cortisol.
HPA AXIS – It’s important to note something called the HPA axis when discussing pituitary hormones as there is a natural and important connection and rhythm between the Hypothalamus, Pituitary and the Adrenal glands.
Adrenocorticotropic hormone (ACTH) is made in the corticotroph cells of the anterior pituitary gland. Its production is stimulated by receiving corticotrophin releasing hormone (CRH) from the Hypothalamus. ACTH is secreted in several intermittent pulses during the day into the bloodstream and transported around the body. Like cortisol (see below), levels of ACTH are generally high in the morning when we wake up and fall throughout the day. This is called a diurnal rhythm. Once ACTH reaches the adrenal glands, it binds on to receptors causing the adrenal glands to secrete more cortisol, resulting in higher levels of cortisol in the blood. It also increases production of the chemical compounds that trigger an increase in other hormones such as adrenaline and noradrenaline. If too much is released, the effects of too much ACTH are mainly due to the increase in cortisol levels which result. Higher than normal levels of ACTH may be due to:
Cushing’s disease – this is the most common cause of increased ACTH. It is caused by a tumor in the pituitary gland (PitNET), which produces excess amounts of ACTH. (Please note, Cushing’s disease is just one of the numerous causes of Cushing’s syndrome). It is likely that a Cortisol test will also be ordered if Cushing’s is suspected.
Cortisol
This is a steroid hormone, one of the glucocorticoids, made in the cortex of the adrenal glands and then released into the blood, which transports it all round the body. Almost every cell contains receptors for cortisol and so cortisol can have lots of different actions depending on which sort of cells it is acting upon. These effects include controlling the body’s blood sugar levels and thus regulating metabolism acting as an anti-inflammatory, influencing memory formation, controlling salt and water balance, influencing blood pressure. Blood levels of cortisol vary dramatically, but generally are high in the morning when we wake up, and then fall throughout the day. This is called a diurnal rhythm. In people who work at night, this pattern is reversed, so the timing of cortisol release is clearly linked to daily activity patterns. In addition, in response to stress, extra cortisol is released to help the body to respond appropriately. Too much cortisol over a prolonged period of time can lead to Cushing’s syndrome. Cortisol over secretion can be associated with Adrenal Cortical Carcinoma (ACC) which can sometimes be grouped within the NET family.
Other hormones related to ACC include:
Androgens (e.g. Testosterone) – increased facial and body hair, particularly females. Deepened voice in females.
Estrogen – early signs of puberty in children, enlarged breast tissue in males.
Aldosterone – weight gain, high blood pressure.
Adrenal Insufficiency (Addison’s Disease) occurs when the adrenal glands do not produce enough of the hormone cortisol and in some cases, the hormone aldosterone. For this reason, the disease is sometimes called chronic adrenal insufficiency, or hypercortisolism.
A tumour outside the pituitary gland, producing ACTH (also called ectopic ACTH). With NETs, this is normally a pNET, Lung/Bronchial NET or Pheochromocytoma.
Multiple Endocrine Neoplasia (MEN). Please note MEN is a group of distinct syndromes not a tumor. Complex area and tends to be multiple instances of some of the tumours above. For a breakdown of MEN types and locations, check out my MEN blog ‘Running in the Family‘
Carcinoid Heart Disease (CHD) (Hedinger syndrome) I’m not really talking directly about a tumour here but thought it would be useful to include a blood test called NT-proBNP. I’ve left a link to my CHD article in the paragraph heading for those who wish to learn more about CHD in general. For those not offered an annual Echocardiogram or are ‘non-syndromic’ NT-proBNP is a screening test that can give an indication of any heart issue which might then need further checks.
Interest Point – NETest by Wren Laboratories – a potential replacement for Chromogranin A?
The Neuroendocrine testing capability from Wren Laboratories is not new. They’ve been around for some time and I remember the “Wren Test” being talked about some years ago. Back then it was receiving mixed reviews from patients and physicians. Looking at where they are in 2020, it looks like they’ve been busy and have new data.
According to their website, the NETest is a non-invasive procedure that uses a blood sample to inform your doctor what the activity of your tumor is at the time your blood was drawn. Use of the NETest provides additional information about disease status that is complementary to imaging and may decrease radiation exposure by decreasing the need for repetitive imaging. NETest provides an assessment of treatment responses in neuroendocrine tumor patients in conjunction with standard clinical assessment. Interpretation of the test will facilitate identification of active disease and enable a determination of the efficacy of the current treatment modality. NETest is as easy as having your blood drawn and provides clinicians and patients with the information to better manage treatment.
Read more by clicking here
The Future – Molecular Markers?
The future is testing using DNA and genes. Exciting but complex – check out this article which involved some NETs.
Summary
This article is designed for patients to understand in a simple way and only covers the basics. Tumour Markers and Hormone levels – complex subject!
If you are a medical professional, I recommend this article:
Herrera-Martínez, A., Hofland, L., Gálvez Moreno, M., Castaño, J., de Herder, W., & Feelders, R. (2019). Neuroendocrine neoplasms: current and potential diagnostic, predictive and prognostic markers, Endocrine-Related Cancer. Retrieved Apr 5, 2019, CLICK HERE
Top 10 Posts & Pages in the last 48 hours (auto updates) (Click the titles to read them)
Thanks for reading.
Personal Facebook. Like this page please.
Blog Facebook. Like this page please.
Awareness Facebook Like this page please.
Sign up for my newsletters – Click Here
My Diagnosis and Treatment History
Check out my online presentations
Check out my WEGO Health Awards
Check out my Glossary of Terms – click here
Please Share this post for Neuroendocrine Cancer awareness and to help another patient
Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors – PRRT vs Everolimus
I was delighted to see this clinical trial which looks at the efficacy of PRRT (Lu177) vs the efficacy of Everolimus (Afinitor). The latter is
Opinion: Let’s attack Cancer metaphors
Since I started blogging, I’ve read dozens of articles on the subject of ‘cancer metaphors’ and in particular their use in describing cancer experiences with
A review of November 2023 on RonnyAllan.NET – Living with Neuroendocrine Cancer
November is always busier as I help spread awareness for 10th Nov (remembering that every day is 10th Nov on my site!). I also managed
European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for Digestive Neuroendocrine Carcinoma
This ENETS guidance paper, developed by a multidisciplinary working group, provides up-to-date and practical advice on the diagnosis and management of digestive neuroendocrine carcinoma, based
Neuroendocrine Cancer – Clinical Esoterica
One of the key awareness messages for Neuroendocrine Cancer is the hormonal syndromes that can often accompany the diagnosis for many people. As it’s a
Neuroendocrine Cancer – The F Words
When I first created my blog in April 2014, I had to find some material to lead up to my 84 mile walk (at the
Laughter is the best medicine
Laughter is important. This is a remastered version of one of my early blog posts. It centred on a ‘get-well’ card I received recuperating in
European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for gastric neuroendocrine tumours (NETs) G1–G3
The ENETS 2023 guideline for gNETs are combined with the guidelines for Duodenal NET (dNET) due to their close relationship in anatomical terms. Gastric neuroendocrine
European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for Duodenal neuroendocrine tumours (NETs) G1–G3
The ENETS 2023 guideline for dNETs are combined with the guidelines for Gastric NET (gNET) due to their close relationship in anatomical terms. But there
A cup of tea
I would also mention those who contributed to my “Tea Fund” which resides on PayPal. You don’t need a PayPal account as you can select a card but don’t forget to select the number of units first (i.e. 1 = £4, 2 = £8, 3 = £12, and so on), plus further on, tick a button to NOT create a PayPal account if you don’t need one. Clearly, if you have a PayPal account, the process is much simpler
Through your generosity, I am able to keep my sites running and provide various services for you. I have some ideas for 2023 but they are not detailed enough to make announcements yet.
This screenshot is from every single post on my website and depending on which machine you are using, it will either be top right of the post or at the bottom (my posts are often long, so scroll down!)
Ronny, do you know what the NETest by Wren Laboratories detects? Some say it is based on DNA evidence of NETs. Have you had any experience with it? They have a lab in London as well as the US. Thanks.
The neuroendocrine neoplasms test (NETest) is a multianalyte liquid biopsy that measures neuroendocrine tumor gene expression in blood. This unique signature precisely defines the biological activity of an individual tumor in real time. The assay meets the 3 critical requirements of an optimal biomarker: diagnostic accuracy, prognostic value, and predictive therapeutic assessment. NETest performance metrics are sensitivity and specificity and in head-to-head comparison are 4-fold to 10-fold more accurate than chromogranin A. NETest accurately identifies completeness of surgery and response to somatostatin analogs. Clinical registry data demonstrate significant clinical utility in watch/wait programs.
However, I don’t see much uptake in the NET Medical world. Not sure why yet.
Thanks so much, Ronny!
This was helpful in the fact that I read the daily updates provided and have been questioning if I need to be connected somewhere else. Not that I would leave this very helpful group, but I have medullary thyroid carcinoid tumors in my upper chest/neck area. None on the thyroid itself. So with that said and after reading your informative article about all the different tumor markers. When it came to calcitonin there wasn’t any information given. If you know of a specific group in that primary I would appreciate it so much. And BTW Ronnie, it truly is amazing that you take the time to do what you do.
I’ll beef up the Calcitonin bit – the aim of the post was just to say what should be tested for which type – so I really covered it! I understand what you mean though. I have never heard of a group just for MTC, sorry – I’ll keep my eyes open. I hope you will stay on all my sites
Rony
Thank you for the informative blogs.This particular one on markers caught my attention. my mother was diagnosed 3 years ago. 2.3cm primary tumor in the stomach with metastasis to the liver 23cms. she has been on sadostatin, primary tumor no longer visible in scans, liver mass down to 17cms. No surgery recommended. Last 6 months cga has been going up. Doctor proposing a dotanc scan to give her direction in treatment plan.what is confusing is despite elevated cga,liver mass remains the same,no carcinoid symptoms,she is not on any ppi.she is onlyon a blood thinner. Why the cga elevation?
apart from tumor load, these are the other causes https://ronnyallan.files.wordpress.com/2018/07/cga.jpg
updated it, thanks for the prompt.
Thanks Ronny, great report, thanks for the information. Jan
While doctors in the US (as anywhere) surely have their preferred markers/tests, I’m finding that more doctors are patient specific when ordering tests. As with everything with this disease, we’re all different. One text for one person may be very indicative of what their disease is up to, that test for another patient may not be as good of an indicator. For example, CgA has always been right on the nose in terms of what my symptoms and scans are showing, so my doctors order it fairly regularly or if I have a sudden change in symptoms. Here’s my question. I didn’t realize that it’s an indicator of bulk or load. Why is it that my CgA changes, dramatically even, while my tumor load does not? I’ve never had surgery. When I started Sandostatin, my CgA dropped from the 2000 range to 250. My tumor load didn’t change. Thanks!
yes, we are all different and many have other illnesses to contend with, some which may be impacting on stability and test results. I can’t really explain why your results are what they are but many reputable sites will tell you that that is what CgA does. I did read one text which said that CgA could decrease as an indicator of therapy success but it didn’t really elaborate how much or what therapies. So, there’s a potential link there. Thinking back to my own experience, my CgA did not reduce after my first surgery (primary small intestine) which coincided with start of Lanreotide treatment. It did, however, return to normal after my liver surgery which would indicate a bulk change. It’s also possible to have a one off increase or reduction and then it goes back to previous trend. Do you have a trend yet?
As I wade through this complex disease I am alway grateful for your dedication to get the word out. How is it that your exact article pops up right when I need it. Some info is still not computing- I think it’s my brain fog. I can still use this as a jumping off place to ask my doctors to help with this Jigsaw. Please keep carrying the torch!
Thanks, keep spreading the word!
Another great post, Ronnie. Very informative — thank you!
Thanks for that article,Ronny. I also by accident or one of your articles found the “diat” to take care of befor the urine test…got the information information from my Doc after asking!
I have another question, if somebody nows about this “side effect” of NET: destroying of nerves. I have some funny feeling in my feet since 5 or 6 years and went to the neurologist. He didn’t find any signs for the to expected diagnosis (Polyneurophathy). I discusse my NET (little intestin, operated 1,5 year ago but sitting there – of course – pretty some years) and he found in the WEB an article that said, that nerve damage is one of the side effects of that illness. Does anybody know anything about this subject? Would be a great help! Thanks!
I’ve never head of this other than as a result of surgery where the route to the offending part of the anatomy has nerves in the way and some damage is unavoidable – for example, I can’t feel my left armpit as well as my right following the removal of some lymph nodes. I’ll keep my ear to the ground though. However, you may find this useful. https://www.google.co.uk/url?sa=t&rct=j&q=&esrc=s&source=web&cd=2&cad=rja&uact=8&ved=0ahUKEwitjf_Hp8HPAhVlLMAKHa5aAgEQFggnMAE&url=https%3A%2F%2Fwww.carcinoid.org%2Fwp-content%2Fuploads%2F2015%2F10%2FParaneoplastic-syndromes-secondary-to-neuroendocrine-tumors.pdf&usg=AFQjCNGxigFMypZ-cKS6f2dm4PsT9azfww&sig2=FnWLIujNi3_fA2O65vfZKg
My husband has just handed in his 5H11A test (urine) No one has ever even mentioned to us that some foods are restricted and this is the fourth time he has has this test. I am shocked because it is such an easy thing to not eat something. Thank you again for your work and information
Another excellent interesting article. Great news about the new test – always hate restricting diet. I only do it for 2 days plus sample day, so will have to try 3 days. Also can confirm problems of measuring in different areas. Have recently transferred from Royal Free to Coventry’s Walsgrave and they measure the Chromogranin A in different units.
Oops! That page can’t be found.
It looks like nothing was found at this location. Maybe try one of the links below or a search?
Recent Posts
* Neuroendocrine Cancer ……. testing testing! * “Not the Stereotypical picture of sick” * Procrastination – it’s a killer * Neuroendocrine Cancer – the diarrhea jigsaw * Please vote for Neuroendocrine Cancer
Most Used Categories
* General (61) * Living with Neuroendocrine Cancer (56) * Awareness (48) * Technical NETs (33) * Daily Blog (29) * Inspiration (24) * Patient Advocacy (23) * Treatment (23) * Survivorship (19) * Diet and Nutrition (8)
Archives
Try looking in the monthly archives. 🙂
Archives
________________________________
cheers ….. sorted …… paaarrrtttyyyyyy
ZBZ5
Sent from my iPad
>
Hi Ron, I was Wondering what type of Liver Surgery You Had For Debulking Or Removing Tumors . I have Carcinoid Syndrome for Now Over 8 years and Am Worried About The Heart ❤️, Too.
I had keyhole, my surgeon was an expert and removed around 60% of my liver, removing tumours from both sides. https://ronnyallan.net/2016/04/12/neuroendocrine-cancer-my-liver-surgery/